Related Experiment Video
Updated: Feb 3, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
The CD44 variant induces K562 cell acquired with resistance to adriamycin via NF-κB/Snail/Bcl-2 pathway
Feng Fan1, Zhang Xiuwen2, Liu Yongyi1
1The Fourth Affiliated Hospital of Jiangsu University, 20 Zhengdong Road, Zhenjiang 212001, China.
Abstract:
Chemotherapy resistance of cancer mainly has innate resistance and acquired drug resistance, which is mainly caused by the gene mutation induced by chemotherapy drugs. Alternative splicing of CD44 has been shown to be associated with the occurrence and development of tumors especially the multidrug resistance, but the underlying mechanism of CD44 in drug resistance remains unclear. Previous studies have found CD44 variants could significantly improve tumor resistance, therefore, we hypothesized the CD44v16, a CD44 variant found in our lab, might confer drug resistance in K562 cell. Through lentiviral expression system, the CD44v16 gene was introduced into the sensitive K562 cell, and the result indicated it could remarkably improve the drug resistance index. Real-time PCR and western blot experiments showed the expressions of protein p65, Bcl-2, Snail, and IKKβ in CD44v16-positive cell group were higher than the CD44v16-negative group. Therefore, we suggest the CD44v16 could induce the K562 cell acquired with resistance to adriamycin via NF-κB/Snail/Bcl-2 pathway, which paved the way for further study the function of CD44v16 in drug resistance.
Insights
The CD44v16 variant enhances chemotherapy resistance in K562 cancer cells by activating the NF-κB/Snail/Bcl-2 pathway. This finding provides insights into acquired drug resistance mechanisms.
Area of Science:
- Cancer Biology
- Molecular Oncology
Background:
- Chemotherapy resistance, both innate and acquired, is a major challenge in cancer treatment, often driven by gene mutations.
- Alternative splicing of CD44 is linked to tumor development and multidrug resistance, but its precise role remains unclear.
Purpose of the Study:
- To investigate the role of the CD44v16 variant in conferring adriamycin resistance to K562 cells.
- To elucidate the molecular mechanisms underlying CD44v16-mediated drug resistance.
Main Methods:
- Introduction of the CD44v16 gene into sensitive K562 cells using a lentiviral expression system.
- Assessment of drug resistance index.
- Real-time PCR and Western blot analysis to measure protein expression levels (p65, Bcl-2, Snail, IKKβ).
Main Results:
- CD44v16 expression significantly increased the drug resistance index in K562 cells.
- Elevated expression of p65, Bcl-2, Snail, and IKKβ was observed in CD44v16-positive cells compared to controls.
- These findings suggest activation of the NF-κB/Snail/Bcl-2 pathway.
Conclusions:
- CD44v16 confers acquired resistance to adriamycin in K562 cells.
- The mechanism involves the activation of the NF-κB/Snail/Bcl-2 pathway.
- This study lays the groundwork for further research into CD44v16's function in drug resistance.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:08Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Histone Variants at the Centromere
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Resistivity
Resistance
Induced Pluripotent Stem Cells